Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
RESOLVE: Significant Improvement in 3-Year Disease-Free Survival with Use of Perioperative SOX in Patients with Locally Advanced Gastric Cancer
Read More
Zanidatamab plus Standard First-Line Chemotherapy Demonstrates Promising Antitumor Activity in Patients with HER2-Positive GEA
Read More
DESTINY-Gastric02: Clinical Efficacy Found with Use of Second-Line Trastuzumab Deruxtecan in Patients with Metastatic Gastric or Esophageal Junction Cancer
Read More
Analysis of the Prognostic Value of Immune Checkpoints in Gastric Adenocarcinoma
Read More
PANTHERA: Triplet Pembrolizumab, Trastuzumab, and Chemotherapy First-Line Therapy Is Effective in HER2-Positive Advanced Gastric/GEJ Cancer Regardless of PD-L1 Status
Read More
ATTRACTION-2: Nivolumab Conveys Survival Benefit for Patients with Advanced Gastric/GEJ Cancer When Used as Treatment Beyond Progression
Read More
KEYNOTE-181: Improved OS in Patients with Advanced Esophageal Cancer Treated with Second-Line Pembrolizumab
Read More
ASCO Releases Clinical Guidelines for the Treatment of Patients with Advanced Esophageal Cancer
Read More
DELIVER: Real-World Data Analysis of Nivolumab Monotherapy in Advanced Gastric Cancer
Read More
CALGB 80803: PET-Directed Therapy After Induction Chemotherapy Yields Promising 5-Year Overall Survival in Patients with Esophageal Cancer
Read More
1
2
3
Page 1 of 3
Results 1 - 10 of 30